Drug Profile

Terlipressin subcutaneous - NanoAntibiotics /PharmaIN

Alternative Names: PGC-C12E-Terlipressin; PHT 101; SC terlipressin- NanoAntibiotics /PharmaIN

Latest Information Update: 21 Mar 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator LAT Pharma; PharmaIN
Developer BioVie
Class Antidiuretics; Antihaemorrhagics; Peptides; Vasoconstrictors; Vasopressins
Mechanism of Action Vasopressin receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Ascites
New Molecular Entity No

Highest Development Phases

Discontinued Ascites

Most Recent Events

21 Mar 2023 Discontinued - Preclinical for Ascites in USA (SC)
28 Jul 2018 No recent reports of development identified for preclinical development in Ascites in USA (SC, Controlled release)
11 May 2017 BioVie plans a phase II trial for Ascites in USA (NCT03107091)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com